TQB2930 injection for advanced solid tumors with HER2 expression
Part of Cancer clinical trials.
This study tests a new injection called TQB2930 designed to treat advanced solid cancers (cancers that have spread) that have HER2 protein on their surface. The goal is to see if this treatment can shrink these tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Advanced solid tumor confirmed to have HER2 protein expression (detected by biopsy)
- Good overall health with ECOG score 0–1 (able to do light activities)
- Expected to live longer than 12 weeks
- At least one measurable tumor lesion visible on imaging
- Recent blood work and organ function tests within acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, TQB2102, for women with advanced or recurrent gynecologic cancers that have some HER2 protein. It may be an option if your cancer has continued to grow after platinum chemotherapy.
This study tests an investigational drug called TQB2922, given as an injection under the skin, for people with advanced non-small cell lung cancer that has not improved with standard treatments. The goal is to see if the drug is safe and helpful.
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
This trial tests an investigational drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to see how safe the drug is and how the body processes it, and it may offer a new option for those with few alternatives.
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.